1. Regarding women with chronic hepatitis B during oral antiviral therapy, childbirth is a rather complex issue. To date, there is no guideline standard that tells you what to do. The biggest concern is the effect of the drug on the development of the embryo in early pregnancy. Although, in animal studies, tebivudine is safe, it is not possible to experiment with people, which is not ethical for humans. Therefore, so far, this is a blind spot and forbidden area in medicine. 2.Tebivudine is designated as a class B drug for pregnancy, and the results of animal experiments show that it is safe and relatively safe for pregnancy compared to other existing nucleoside analogues, but there are not many data about the safety of pregnancy in humans. In contrast, although lamivudine is classified as a class C drug for pregnancy, there are a large number of data on the retrospective safety of human pregnancy due to the early availability of the drug, coupled with the large amount of data in the HIV-infected population. Even so, the use of this class of drugs in early pregnancy is not recommended. A relatively safe and conservative recommendation is to use telbivudine to achieve E antigen serologic conversion (to minor triplet), HBVDNA below the detection line, and normal liver function, then consolidate treatment for at least one year, and stop the drug for 3 months after pregnancy; or switch to interferon therapy to achieve E antigen serologic conversion (to minor triplet), HBVDNA below the detection line, and normal liver function, and stop the drug for 6 months after pregnancy. In case of recurrence of hepatitis in mid- to late pregnancy, antiviral therapy with lamivudine or telbivudine may be given. However, the practical workability of this regimen needs to be explored. This is because only a minority of people achieve the above treatment goals and can stop the drug! 4. The discussion of such an important program and decision cannot be satisfactorily achieved by the internet and text, but requires face-to-face communication and exchange, fully weighing the pros and cons. For well-known reasons, pregnancy is not easy for women of reproductive age at the present time, and in addition, the risk of pregnancy at advanced ages will certainly increase as the duration of antiviral therapy progresses. How to choose a more appropriate individual plan for the specific situation of the individual certainly requires a full face-to-face communication and discussion.